EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 19 / No 2 (Février 2003) Med Sci (Paris), 19 2 (2003) 201-210 References
Free Access
Issue
Med Sci (Paris)
Volume 19, Number 2, Février 2003
Page(s) 201 - 210
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2003192201
Published online 15 February 2003
  1. Jonkers J, Berns A. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim Biophys Acta 1996; 1287: 29–57. [Google Scholar]
  2. Mikkers H, Allen J, Knipscher P, et al. Highthroughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 2002; 32: 153–9. [Google Scholar]
  3. Lund AH, Turner G, Trubetskoy A, et al. Genome-wide retroviral tagging of genes involved in cancer in Cdkn2adeficient mice. Nat Genet 2002; 32: 160–5. [Google Scholar]
  4. Suszuki T, Shen H, Akagi K, et al. New genes involved in cancer identified by retrovirus tagging. Nat Genet 2002; 32: 166–74. [Google Scholar]
  5. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059–64 [Google Scholar]
  6. Dalla-Favera R, Bregni M, Erikson J, et al. Human cmyc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79: 7824–7. [Google Scholar]
  7. Taub R, Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plastocytoma cell. Proc Natl Acad Sci USA 1982; 79: 7837–41. [Google Scholar]
  8. Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukemia. Nature 1983; 306: 239–42. [Google Scholar]
  9. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372: 143–9. [Google Scholar]
  10. Rabbitts TH. Chromosomal translocation master genes, mouse models and experimental therapeutics. Oncogene 2001; 20: 5763–77. [Google Scholar]
  11. Scandura JM, Boccuni P, Cammenga J, Nimer SD. Transcription factor fusions in acute leukemia. Oncogene 2002; 21: 3422–44. [Google Scholar]
  12. Scheijen B, Griffin JD. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 2002; 21: 3314–33. [Google Scholar]
  13. Zhu J, Emerson SG. Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene 2002; 21: 3295–313 [Google Scholar]
  14. Künstle G, Laine J, Pierron G, et al. Identification of Akt association and oligomerisation domains of the Akt kinase coactivator TCL1. Mol Cell Biol 2002; 22: 1513–25. [Google Scholar]
  15. Levy ER, Parganas E, Morishita K, et al. DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome. Blood 1994; 83: 1348–53. [Google Scholar]
  16. Lallemand-Breitenbach V, Zhu J, de Thé H. La leucémie aiguë promyélocytaire: un paradigme des traitements ciblés sur l’oncogène? Med Sci 2001; 17 : 14–22. [Google Scholar]
  17. Poirel H, Bernard O. Implication des gènes du CBF dans la leucémogenèse. Hématologie 2000; 6 : 30–6. [Google Scholar]
  18. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307–16. [Google Scholar]
  19. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nuclear protein gene, NPM in non-Hodgkin’s lymphoma. Science 1994; 263: 1281–4. [Google Scholar]
  20. Popovici C, Adélaïde J, Ollendorff V, et al. Fibroblast growth factor receptor 1 is fused to FIM in 210 stem cell myeloproliferative disorder with t(8;13) (p12;q12). Proc Natl Acad Sci USA 1998; 95: 5712–7. [Google Scholar]
  21. Guasch G, Mack GJ, Popovici C, et al. FGFR1 is fused to the centrosomeassociated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9) (p12;q33). Blood 2000; 95: 1788–96. [Google Scholar]
  22. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278: 1309–12. [Google Scholar]
  23. Kuno Y, Abe A, Emi N, et al. Constitutive activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12) (q22;p12). Blood 2001; 97: 1050–5. [Google Scholar]
  24. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukemia in children. Lancet 1999; 354: 1499–503. [Google Scholar]
  25. Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA 2002; 99: 8242–7. [Google Scholar]
  26. Liu Y, Hernandez AM, Shibata D, Cortopassi GA. Bcl2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 1994; 91: 8910–4. [Google Scholar]
  27. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118–22. [Google Scholar]
  28. Pabst T, Meuller BU, Zhang P, et al. Dominant-negative mutations of mutations of C/EBPα, encoding CCAAT/enhancer binding protein alpha, in acute myeloid leukemia. Nat Genet 2001; 27: 263–70. [Google Scholar]
  29. Gombart AF, Hofmann WK, Kawano S, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002; 99: 1332–40. [Google Scholar]
  30. Mercher T, Coniat MB, Monni R, et al. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proc Natl Acad Sci USA 2001; 98: 5776–9. [Google Scholar]
  31. Ma Z, Morris SW, Valentine V, et al. RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 2001; 28: 220–1. [Google Scholar]
  32. Shivadsani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 1997; 16: 3965–73. [Google Scholar]
  33. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA 1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32: 148–52. [Google Scholar]
  34. Song WJ, Sullivan MG, Legare RD, et al. Haploinsuffiency of CBFA2 (AML1) causes familial thrombocytopenia with propensity to develop acute myelogenous leukemia (FPD/AML). Nat Genet 1999; 23: 166–75. [Google Scholar]
  35. Brown L, Cheng JT, Chen Q, et al. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J 1990; 9: 3343–51. [Google Scholar]
  36. Cayuela JM, Madani A, Sanhes L, Stern MH, Sigaux F. Multiple tumorsuppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 1996; 87: 2180–6. [Google Scholar]
  37. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTENdeficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314–9. [Google Scholar]
  38. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 2001; 98: 10320–5. [Google Scholar]
  39. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS- 341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–6. [Google Scholar]
  40. Huettner CS, Zhang P, Van Etten RA, Tenen D. Reversibility of acute Bcell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24: 57–60. [Google Scholar]
  41. Felsher DW, Bishop M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4: 199–207. [Google Scholar]
  42. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR/ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–7. [Google Scholar]
  43. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 5: 433–43. [Google Scholar]
  44. Liao AT, Chien MB, Shenoy N, et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002; 100: 585–93. [Google Scholar]
  45. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189: 1043–52. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.